Eli Lilly and GSK drive South Korea’s drug licensing activity
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Drug Development
Uncertainty around tariffs is a disincentive for pharma onshoring in the US
Atombeat and BioDuro link for peptide drug discovery platform
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
Farxiga and Jardiance pose affordability issues, says Maryland drug board
Can rare disease research in the US thrive under the new administration?
Ten years of Rare Pediatric Disease Designation: impact on drug approvals
EC approves argenx’s efgartigimod alfa for CIDP treatment
